Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2019
Reporting Period: Quarter ended June 30, 2019
Context: This filing serves to announce the issuance of a press release containing financial results for the second quarter of 2019. The company is designated as an emerging growth company.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. The actual revenue, profit, cash flow, margins, debt, and liquidity figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text. Therefore, no specific financial metrics can be extracted from this document.
Material Changes
The filing text does not provide specific details regarding material changes in financial performance compared to prior periods. It only confirms that results for the quarter ended June 30, 2019, were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on August 7, 2019, which presumably contains management commentary, guidance, and outlook, but the content of that release is not present in this text.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 7, 2019) for specific Q2 2019 revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter growth rates in the referenced press release.
- Check for updated forward-looking guidance or outlook statements in the press release.
- Confirm the company's status as an emerging growth company and any related election regarding extended transition periods for accounting standards.